Research On The Path Selection And Effect Of Chinese Concept Stock Regression Essay Topic

The early domestic listing threshold is high,many emerging enterprises in order to develop overseas listing.However,since 2010,a large number of Chinese concept companies have chosen to return to China for development,and the return of Chinese concept shares has gradually become one of the hot topics in the domestic capital market.This paper takes WuXi PharmaTech as the research object,and studies the reasons for its decision to return to the domestic market,the path of "spin-off + IPO" and the effect after the return,so as to provide theoretical and practical guidance for Chinese concept stocks to return.This paper uses the literature research and case study to analyze the return reason,"spin-off + IPO" path,and the effect after the return of WuXi PharmaTech,reaching the following conclusions: the main reason of WuXi PharmaTech regression is that the domestic market valuation is lower than domestic companies in the same industry,the company's long-term development strategy is not recognized as well as the regression can emerge the markets in China.In terms of the path selection of WuXi PharmaTech,this paper studies the two stages from privatization delisting to re-listing,and concludes that the reasons for its final return to the path of "spin-off + IPO" are as follows: the business of WuXi PharmaTech is suitable for spin-off and provides financial support for the a-share IPO of the parent company,which is the basis for successful return.At the same time,backdoor is limited so that it can only seek other regression paths.The domestic economy continued to improve,and the regulatory authorities opened A green channel for Chinese concept stocks to return to IPO,which also promoted their success in regression.After the return of WuXi PharmaTech,the company's business performance and company value have been greatly improved,and the market performance is good.Innovation point of the article is research perspective innovation,in recent years,stock return has always been A hot topic,and it belongs to one of the relatively new research subjects.This article selected the company named WuXi PharmaTech as the study case,because it is the first Chinese stock company return to A shares successfully using the path of "spin-off + IPO",the design of its regression is novelty,and it has certain reference value for other Chinese stock companies.